Now researchers have designed a liquid biopsy that tells doctors how likely a patient is to respond to a specific treatment, even before it begins. The test has the potential to be gamechanging because it means patients could be offered alternative options, and avoid treatments that won’t help them, boosting their chances of beating the disease.